PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival - Wikidata - wikimedia - TriplyDB

PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival

PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival

http://www.wikidata.org/entity/Q35146249

about

Lymphoma Immunotherapy: Current Status Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?The clinical development of obinutuzumab for the treatment of follicular lymphoma.Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.Immune checkpoint blockade for hematologic malignancies: a review PD1 is highly expressed in diffuse large B-cell lymphoma with hepatitis B virus infection.Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.PD-L1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer.PD-1 expression on the surface of peripheral blood CD4(+) T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma.Immune checkpoint blockade in lymphoid malignancies.The emerging role of immune checkpoint inhibition in malignant lymphoma.Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.Differential Expression of Immune Checkpoint Modulators on In Vitro Primed CD4(+) and CD8(+) T Cells.PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load.Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients.Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database.Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma.Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?T cells expressing checkpoint receptor TIGIT are enriched in follicular lymphoma tumors and characterized by reversible suppression of T-cell receptor signaling.PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.Clinical Development of PD-1 Blockade in Hematologic Malignancies.T follicular helper cells: a potential therapeutic target in follicular lymphoma.Unmet needs in the first-line treatment of follicular lymphoma.Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.T-cell subsets in lymph nodes identify a subgroup of follicular lymphoma patients with favorable outcome.MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma.Evaluation of costimulatory molecules in dogs with B cell high grade lymphoma EBV infection determines the immune hallmarks of plasmablastic lymphoma PD1 cells associate with clusters of proliferating B-cells in marginal zone lymphoma

P2860

Q26782902-4A0838CB-02D9-43BD-AED4-12C9D568A788 Q28076071-2EF21920-E05E-46CE-BEEF-A8ABCD2A4657 Q33565265-9009E361-DE40-4C0B-8057-318B708A4655 Q33638083-1FDBFC02-FA74-4991-8A97-5D6F83761C39 Q33645590-15A2C24E-A5D2-41A1-A943-05679DC1494E Q33853605-66FCA337-C9D9-4F9A-8A31-FD86EBA61213 Q36043066-88AA315F-B475-477B-9D11-2B3A254A8023 Q36395999-DE6E920C-C724-4085-A1EA-FCABF27BEF9F Q36522770-75A833CF-C35E-4068-8869-079066946162 Q37352695-A75344A2-6490-4EE3-8374-F2893EC5082E Q37429917-B14F8DD0-AD3B-4032-AB20-51C2CDE9852E Q38710672-E75D6891-CD0E-4F4F-AF47-77F95C77F05C Q38791036-1B28586F-1932-4627-879A-851835E6454C Q38795442-C5D9CC44-F146-4A11-A80B-70D9C5D70CAF Q38845203-A8666BF8-F34A-4D34-B020-F1794738FC67 Q38931346-8A013F58-2BBC-4EDC-B82B-45A6607CB634 Q39093439-A83D071F-BA00-42B0-B4F1-B5220E17949B Q39237785-0D37E5D7-5696-4EF3-A119-3BF4B32F8F3B Q39353147-77835877-BF61-4997-8E7A-F640C0C8285E Q39937262-CE90E42E-0669-4659-B423-D234E7BEF6D7 Q42079188-89B109A3-A9EE-4620-94FD-7031FAC8122B Q47120629-082690C6-4A65-4E47-AF12-BA00C63244CE Q47271511-1FEDA4B1-6F57-4302-8334-E3A47FDD0098 Q47424027-A75AE665-76CD-4CDB-AB23-444F35D2FADB Q47952363-DEDD330C-951F-41B7-A5B7-EBD9339EFCF2 Q48156058-A76283FA-6912-4401-9EC1-2EF69BFCCE4A Q48526801-57371110-042D-420D-985E-029634EECEC9 Q49702451-0D55D85B-FD6B-46D0-A76F-460C4761AB00 Q50710717-F4C353E4-5603-42C4-AFF7-BAE52A04DA27 Q51804722-0CB104B9-963B-405A-B703-E111AB11C34B Q53019021-F02AEB5E-BF27-48F2-B99C-4D16B7205C92 Q55021517-B22E7D22-52BA-4FD2-8B6F-0BC229F0610B Q56890877-D7F640AE-C9EA-4671-A582-8E5064817E6F Q56968100-381A1F27-B691-4665-B3E7-069C5664B697 Q57156812-2FBB2461-B2EE-408E-8339-E2BC0A107191

P2860

PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival

http://www.wikidata.org/entity/Q35146249

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

PD-1 expression defines two di ...... tially impact patient survival

@ast

PD-1 expression defines two di ...... tially impact patient survival

@en

type

label

PD-1 expression defines two di ...... tially impact patient survival

@ast

PD-1 expression defines two di ...... tially impact patient survival

@en

prefLabel

PD-1 expression defines two di ...... tially impact patient survival

@ast

PD-1 expression defines two di ...... tially impact patient survival

@en

P1433

Q35146249-1057286C-DBDB-4075-BC10-56511B8FF742

P1476

Q35146249-C5D70CCA-F3C8-4A7C-BD57-681996587BF8

P2093

Q35146249-0055210C-59B7-4BC1-A84C-7313684A8BDD

Q35146249-3EB516D9-454B-435F-89B5-D55CC78A4422

Q35146249-435B2E53-10F7-41AA-950F-9841DC6BA4B6

Q35146249-7E14053A-1282-4E99-AF65-963ED886592B

Q35146249-AEA95976-06D4-4929-9A34-66DC3D024494

Q35146249-F0DD691F-607A-45FF-A6E1-3BCB5FE493E0

P2860

Q35146249-00C73F50-56CE-489C-B455-2CDE8C1073D4

Q35146249-0510EF7B-E037-46C8-A424-C0F5E3CA2357

Q35146249-07BCBC6F-FB59-4162-B527-2C30B5A49E01

Q35146249-0AA8DE47-AC47-4765-B5C9-5F673A727B75

Q35146249-1BD474F3-201F-4462-87F2-2AA3B1D1C37D

Q35146249-24E336F9-9786-4264-8802-88CF24C82856

Q35146249-2517AB24-9C95-4191-8719-4EEC9505B42C

Q35146249-337DC64C-A942-4A51-917A-9C579A73546E

Q35146249-386E7972-E1E7-4373-A43B-36409F4BDAA0

Q35146249-45FEBA2B-D471-49A0-9D7E-CEA6EE8131ED

P2888

Q35146249-2E380AD9-F06F-4CFB-B8F9-BA432B74F10E

P304

Q35146249-B5A309C6-A425-4338-8BF3-B38C537294C4

P31

Q35146249-20A7A97D-C419-4A8D-B5E1-E3CCD44DC2E0

P356

Q35146249-492F3FAE-BFBB-4BF7-B8A9-485ACECEBC37

P478

Q35146249-6E9783DE-9D1D-4444-A849-ADB2688EBE79

P577

Q35146249-49AD5771-46EB-429F-9FC3-B3A2762CB81D

P5875

Q35146249-B17E15DD-51DE-4287-BB73-1CEA890709FC

P6179

Q35146249-7EB9495F-6920-4197-97EE-250DF3194108

P698

Q35146249-0B40E7FC-B9A1-4402-8C76-E10F6E9048E7

P921

Q35146249-2CC2011E-3C99-43F7-8DF6-66D6CE423021

P932

Q35146249-AE584542-F0E9-4746-A673-34F88725454B

P356

P1433

Blood Cancer Journal

P1476

PD-1 expression defines two di ...... tially impact patient survival

@en

P2093

A J Novak

http://www.w3.org/2001/XMLSchema#string

B Xiu

http://www.w3.org/2001/XMLSchema#string

D M Grote

http://www.w3.org/2001/XMLSchema#string

S C Ziesmer

http://www.w3.org/2001/XMLSchema#string

S M Ansell

http://www.w3.org/2001/XMLSchema#string

Z-Z Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma.

Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection.

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.

Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction.

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma

IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma.

CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function

P2888

P304

e281

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BCJ.2015.1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273507865

http://www.w3.org/2001/XMLSchema#string

P6179

1051577577

http://www.w3.org/2001/XMLSchema#string

P698

25700246

http://www.w3.org/2001/XMLSchema#string

P921

P932

4349259

http://www.w3.org/2001/XMLSchema#string